TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced amendments to its Articles of Association following the completion of a placement of new H shares, which increased the company’s total issued shares. This adjustment in the share capital structure reflects the company’s strategic efforts to enhance its market presence and operational capacity, potentially impacting its stakeholders by aligning its governance documents with its expanded capital base.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, specializing in the development and commercialization of innovative cancer immunotherapy products. The company focuses on leveraging the body’s immune system to combat cancer, positioning itself as a key player in the biopharmaceutical industry.
Average Trading Volume: 3,686,108
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.46B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.